GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE347nnn/GSE347086/primaryOK200TranscriptomicsMus musculusExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347086GEOGSEfalseCombined transcriptomic profiling of anti-PD-1 immunotherapy and FGFR inhibitor AZD4547 in a CT26 colorectal cancer syngeneic mouse modelThis study investigated the transcriptomic effects of anti-PD-1 immunotherapy combined with the FGFR inhibitor AZD4547 in a CT26 colorectal cancer syngeneic mouse model. BALB/c mice bearing CT26 subcutaneous tumors were randomized into four treatment groups: Rat IgG2a + PBS (control), anti-PD-1 antibody (anti-PD-1), FGFR inhibitor AZD4547 (FGFRi), and AZD4547 plus anti-PD-1 combination (FGFRi+anti-PD-1). Total RNA was extracted from tumor tissues and subjected to paired-end bulk RNA-seq on the Illumina NovaSeq 6000 platform (PE150). Clean reads were aligned to the mouse reference genome GRCm38/mm10, and gene expression was quantified as raw counts and FPKM, followed by differential expression and enrichment analyses.2026/09/26GSE347086GSM10045790GSM10045792GSM10045791GSM10045787GSM10045786GSM10045789GSM10045788GSM10045783GSM10045782GSM10045785GSM10045784GSM10045781GSM10045780GSM10045776GSM10045775GSM10045778GSM10045777GSM10045772GSM10045794GSM10045793GSM10045774GSM10045796GSM10045795GSM10045773GSM1004577924247347086Mus musculus